| Ytd | -37.32% | |
| 1y | 44.40% |
| Open | 6.26 | Prev Close | 6.33 | Low | 6.26 | High | 6.75 | Mkt Cap | 335.31M |
| Vol | 1.61M | Avg Vol | 153.78K | EPS | -1.11 | P/E | N/A | Forward P/E | N/A |
| Beta | -2.47 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 6.39 | 200-d Avg | 6.83 | 1yr Est | 0.00 |
CapsoVision, Inc.3,163,444 Shares of Common Stock We are offering 3,163,444 shares of our common s
Zimmer Biomet (NYSE: ZBH - Get Free Report) and CapsoVision (NASDAQ: CV - Get Free Report) are both
BlackRock Inc. purchased a new position in shares of CapsoVision, Inc. (NASDAQ: CV) during the secon
SARATOGA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-st
[url="]Alnylam Pharmaceuticals, Inc[/url]. (Nasdaq: ALNY), the leading RNAi therapeutics company, to
CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript
CapsoVision NASDAQ: CV reported second-quarter revenue growth as sales of its CapsoCam Plus capsule
CapsoVision (NASDAQ:CV) released second-quarter financial results and hosted an earnings call on Thu
CapsoVision, Inc.$250,000,000Common StockPreferred StockWarrantsRightsUnits From time to time, we
SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-sta
SARATOGA, Calif. , Aug. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-st
SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-sta
SARATOGA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (Nasdaq: CV), a commercial-sta
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Ado
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH S
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Mon
CapsoVision NASDAQ: CV reported steady first-quarter revenue and said it continues to advance artifi
CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript
CapsoVision (NASDAQ:CV) reported quarterly losses of $(0.15) per share which missed the analyst cons
SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stag
SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-st
CapsoVision (NASDAQ: CV - Get Free Report) and Nanovibronix (NASDAQ: FEED - Get Free Report) are bot
Benchmark analyst Bruce Jackson maintains CapsoVision (NASDAQ:CV) with a Speculative Buy and lowe
CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript
CapsoVision (NASDAQ:CV) reported quarterly earnings of $0.02 per share which beat the analyst consen
CapsoVision, Inc. (the "Company") (NASDAQ: CV), a commercial-stage medical technology compan
Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results Reports Prelimina
Benchmark analyst Bruce Jackson maintains CapsoVision (NASDAQ:CV) with a Speculative Buy and rais
U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, C